|
|
|
17.08.26 - 08:30
|
Enhertu improved PFS in 1L HER2m lung cancer (Cision)
|
|
|
17 August 2026
Enhertu demonstrated statistically significant and clinically meaningful improvement in
progression-free survival as 1st-line treatment of patients with HER2-mutant advanced
non-small cell lung cancer in
DESTINY-Lung04 Phase III trial
AstraZeneca and Daiichi Sankyo's Enhertu is the first and only
HER2-directed medicine to improve progression-free survival
over global standard of care in a Phase III trial in this setting
Positive high-level results from the DESTINY-Lung04 Phase III trial showed Enhertu (trastuzumab deruxtecan) demonstrated a statistically...
|
|
|
10.08.26 - 12:36
|
Innovent and Daiichi Sankyo sign deal for Vanflyta in China (PBR)
|
|
|
Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China.
The post Innovent and Daiichi Sankyo sign deal for Vanflyta in China appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
03.08.26 - 08:06
|
Daiichi Sankyo: Weaker Yen Boosts Topline Growth (Bloomberg)
|
|
|
Daiichi Sankyo President and CEO Hiroyuki Okuzawa says a weaker yen is an advantage for topline growth, but would also weigh on expenses outside of Japan. He appeared exclusively on Bloomberg's Insight with Haslinda Amin. (Source: Bloomberg)...
|
|
|
|
|
31.07.26 - 10:33
|
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results (Business Wire)
|
|
|
Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.
“Daiichi Sankyo delivered strong revenue growth in the first quarter of fiscal year 2026 as we began execution of our new Five-Year Business Plan,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “Three new U.S. approvals for Enhertu and Datroway were received in a single week in May, underscoring the continued strength of our portfolio where we anticipate delivering more than 20 new indications across five medicines by 2030. These results reinforce the durability of our growth trajectory and support our outlook for fiscal 2026 and beyond.”
Q1 FY2026 Results
Global revenue increased 21.1% year-over-ye...
|
|
|
|
|
31.07.26 - 08:54
|
Datroway approved in EU for TNBC (Cision)
|
|
|
31 July 2026
Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy
Approval based on TROPION-Breast02 Phase III trial results where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
Datroway now approved for two breast cancer indications in the EU
AstraZeneca and Daiichi Sankyo's Datroway (datopotamab...
|
|
|
|
|
|
|
|
|
|
|
29.06.26 - 08:42
|
Enhertu approved in EU for HER2+ solid tumours (Cision)
|
|
|
29 June 2026
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which demonstrated clinically meaningful responses across a broad range of tumours
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC]...
|
|
|
29.06.26 - 08:06
|
Datroway recommended for approval in EU for TNBC (Cision)
|
|
|
29 June 2026
Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
Recommendation based on TROPION-Breast02 Phase III trial where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
If approved, Datroway has the potential to be the first TROP2-directed antibody drug conjugate for patients in the EU with a...
|
|
|
|
|
|
|
|
|
26.05.26 - 08:01
|
Datroway approved in US for 1L triple-negative BC (Cision)
|
|
|
26 May 2026
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo's Datroway is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 Phase III trial
Datroway has the potential to become the new standard of care in this setting...
|
|
|
26.05.26 - 08:01
|
Enhertu recommended in EU for HER2+ solid tumours (Cision)
|
|
|
26 May 2026
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours
If approved, Enhertu would become the first HER2-directed therapy and
antibody drug conjugate to receive a tumour agnostic indication in the EU
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
